Jpmorgan Chase & CO Caribou Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 464,027 shares of CRBU stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
464,027
Previous 549,053
15.49%
Holding current value
$1.09 Million
Previous $2.82 Million
73.03%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CRBU
# of Institutions
141Shares Held
53.3MCall Options Held
32.5KPut Options Held
89.8K-
Black Rock Inc. New York, NY6.95MShares$16.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.54MShares$10.6 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.16MShares$9.74 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA4.08MShares$9.56 Million0.34% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.62MShares$6.14 Million0.0% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $142M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...